Home › Compare › SPKTF vs ABBV
SPKTF yields 1538.46% · ABBV yields 3.06%● Live data
📍 SPKTF pulled ahead of the other in Year 1
Combined, SPKTF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SPKTF + ABBV for your $10,000?
Spectra Products Inc. manufactures and markets bus and truck transportation safety equipment in Canada and the United States. It offers brake and wheel-end monitoring equipment as an after-market product through transportation dealers, distributors, and direct sales to fleet operators. The company also provides Brake Safe, a visual brake stroke indicator system that permits vehicle drivers and maintenance to visually check the brake adjustment condition of a truck and trailer or bus equipped with an air brake system; and Brake Inspector, an electronic in-cab air brake diagnostic system. In addition, it offers Termin-8r, an anti-corrosion spray lubricant; Zafety Lug Lock that prevents wheel-end lug nuts from loosening leading to wheel damage or loss; Hub Alert, a heat sensitive label, which is applied to each wheel hub of trucks, trailers, buses, and off-road vehicles to provide an early warning of critical temperature threshold levels; and Anti-Seize Cotter Pin, which keeps clevis pins from seizing in slack adjusters. The company was formerly known as Spectra Inc. and changed its name to Spectra Products Inc. in January 2020. Spectra Products Inc. was incorporated in 1994 and is based in Toronto, Canada.
Full SPKTF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.